Rare disease biotech

Zevra Therapeutics has recently made a series of notable announcements that have captured the attention of investors, analysts, and those following developments in the rare disease pharmaceuticals sector. As it undertakes strategic organizational shifts, reports strong financial metrics, and earns supportive analyst forecasts, the company appears committed to building a robust pipeline of treatments for…